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Abstract Using high-performance liquid chromatography, gas- 
chromatography and chromato-mass pectrometry methods a 
novel endogenous cyclic dipeptide cyclo-prolylglycine was 
identified in rat brain. Its content according to gas chromato- 
graphy is 2.8 + 0.3 nmol/g wet brain. Synthetic cyclo-prolylgly- 
cine has demonstrated antiamnesic activity in the passive 
avoidance test in rats at a dose of 0.1 mg/kg i.p. Cyclic dipeptide 
cyclo-prolylglycine seems to be a memory facilitating substance 
and its presence in rat brain suggests the existence of a new 
mechanism of memory regulation. 
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displays activity due to interaction with one vasopressin re- 
ceptor subtype. We have found out, however, that unlike 
piracetam, which facilitates the initial processing of memory 
engram as well as consolidation, the dipeptide pGlu-Asn-NH2 
improved only the phase of information input and retrieval, 
but did not influence consolidation [10]. On the other hand, 
proline-containing dipeptide analogues of piracetam facili- 
tated consolidation [11]. The cyclic dipeptide cyclo-(Pro-Gly) 
turned out to be the most active of them [12]. This cyclic 
dipeptide can be assumed to be one of the endogenous ligands 
of hypothetic 'nootropic receptors', which selectively regulates 
the processes of training and memory. This work is devoted to 
the identification of endogenous cyclo-(Pro-Gly) in rat brain. 
1. Introduction 
In spite of the fact that many neuropeptides influence train- 
ing and memory, only some of them, it is presumed, directly 
control these processes [1,2]. The best known is the major 
arginine-vasopressin metabolite, [pGly4,Cytr]AVP(4-9), which 
facilitates the consolidation stage of memory formation [3,4]. 
At the same time there are exogenous medicines, so-called 
nootropics, with piracetam as the main representative, which 
selectively facilitate processes of training and memory [5,6]. In 
1985 we [7] put forward the hypothesis that the classical noo- 
tropic piracetam acts as a peptidomimetic. On the basis of this 
hypothesis active dipeptide analogues of piracetam were re- 
ceived that possessed proline or pyroglutamic acid as their N- 
terminal pyrrolidine-containing amino acid. Among the de- 
signed pyroglutamyl-containing dipeptides pyroglutamylas- 
paragine amide turned out to be the most active [8]. It dis- 
played nootropic activity in the passive avoidance test in rats 
at a dose of 0.01 mg/kg i.p. This effect depended on the 
stereochemistry of both amino acid residues [9]. The structure 
of pyroglutamylasparagine amide coincides with an N-ter- 
minal fragment of a major vasopressin metabolite, 
[pGlu4,Cyt6]AVP(4-9), responsible for the central effects of 
the latter [3]. These facts allowed us to assume that piracetam 
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Abbreviations: AA, antiamnesic activity; amu, atomic mass unit; 
AVP, arginine vasopressin; FAB, fast atom bombarding mass 
spectrometry; GC, gas chromatography; GC-MS, gas chromatogra- 
phy-mass pectrometry; HPLC, high-performance liquid chromato- 
graphy; MES, maximal electroconvulsive shock; MOPS, 3- 
morpholinopropanesulfonic ac d; PDAH, pyrrolidino-[1,2-a]-2,6-dia- 
zacycloheptanedione-l,5; RIC, relative ion current; SIM, selected ion 
monitoring; UV, ultraviolet 
2. Materials and methods 
2.1. Chemicals 
Diketopiperazine cyclo-prolylglycine (m.p. 213-214°C, [a]~ 2° 214°C 
in H20) was synthesized according to [13]. Pyrrolidino[1,2-a]-2,6-dia- 
zacycloheptanedione-l,5 (m.p. 169-1700C) was synthesized according 
to [14]. Acetonitrile (HPLC grade) and 3-morpholinopropanesulfonic 
acid (MOPS) were obtained from Merck. 
2.2. Animals 
Male outbred albino rats (18~240 g) were used in the experiments. 
The animals were housed under standard conditions and were allowed 
free access to food and water. 
2.3. Preparation of extracts 
Five animals were killed by decapitation, the brain was removed, 
washed thoroughly with ice-cold 0.9% saline, then crushed and im- 
mediately homogenized in 3 volumes of H20 at 0°C. The homogenate 
was shaken for 10 min with 5 volumes of acetonitrile, then centrifuged 
at 9000 rpm for 10 min at 2°C and dried under a stream of N2 at 
room temperature. The dry residue was redissolved in 2 ml H20 and 
applied on an HPLC column. 
2.4. High-pressure liquid chromatography 
A Beckman 110B chromatograph equipped with the Tracor-970A 
absorbence detector UV (detection at 220 nm) was used. Chromato- 
graphy was conducted on an Eiconosil C18 column, 250 ×4.6 mm, 10 
p.m, at a flow rate of 1.0 ml/min. The probe volume was 20 ~tl. The 
elution was carried out with acetonitrile containing 0.005 M MOPS 
(2:98 v/v). Fractions with a retention time corresponding to that of 
synthetic yclo-(Pro-Gly) were combined, evaporated on a rotary eva- 
porator to a small volume, then freed of MOPS by rechromatography 
on an Ultrasphere ODS column 250 × 4.6 mm, particle size of 5 ~m, 
in system acetonitrile:water (2:98 v/v). The combined fractions left 
after rechromatography of the total material were evaporated to dry- 
ness on a rotary evaporator, the residue was dissolved in 100 ~tl of 
acetonitrile and used for GC and mass spectrometry. 
2.5. Gas chromatography 
A model 3700 gas chromatograph (Russia) equipped with a flame 
ionization detector was used. GC was performed using a glass 2 m × 4 
mm I.D. column packed with 3% OV-17 on Chromosorb G 125-150 
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mesh washed 0.1 N NaOH. Nitrogen was used as the carrier gas. Gas 
flow rates were 40 ml/min (nitrogen), 30 ml/min (hydrogen), and 300 
ml/min (air). A 3 111 aliquot was injected at 220°C. The oven tempera- 
ture was 205°C, the detector temperature was 250°C and the bead 
power was set at 16 pA. 
2.6. Mass spectrometry 
Fast atom bombarding mass spectrometry (FAB) was performed 
using a FAB 50 device (Kratos, USA). Xenon was used as a reagent 
gas (8 keV). Glycerol was used as a standard matrix. 
Chromato-mass pectrometric analysis was carried out with a Fin- 
nigan MAT SSQ-710 mass spectrometer. A Varian 3400 gas chroma- 
tograph equipped with a DB-5 glass capillary column (30 mX0.248 
mm I.D., 0.25 ~tm film thickness, J. and W., Folsom, CA, USA) was 
used for sample separation with helium as a carrier gas at 30 ml/min 
flow rate. A 0.3 ~tl aliquot was injected at 250°C. The oven tempera- 
ture was programmed from 40°C (held 0 min) to 250°C at 10°C/min, 
the latter temperature was then maintained until the end of the run. 
The total run time was 37 rain. The GC-MS interface temperature was 
250°C. The GC-MS system was operated in the electron impact mode 
with full scan at 1.34 u/s. The mass range was set for 50-650 amu. The 
source parameters were selected as ion energy 70 eV, ionization cur- 
rent 400 mA and ion source temperature 150°C. 
Direct probe mass spectrometry was performed on the same device 
(Finnigan MAT SSQ-710) operated in the electronic impact mode 
with multiple selected ion monitoring (SIM) turned on m/z 154, 
126, 111, 98, 83. The ionization energy was 70 eV. Ion source tem- 
perature was programmed from 25°C to 350°C at 162.5°C/min, then 
the temperature was held at 350°C for 4 min. 
2. 7. Recovery 
Pyrrolidino-[1,2-a]-2,6-diazacycloheptanedione-l,5 (PDAH), a horn- 
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Fig. l. HPLC separation of rat brain acetonitrile xtract on an Ei- 
conosil Cls column (250x4.6 mm, 10 lxm particle size), UV detec- 
tion at 220 nm. Mobile phase 98% 0.005 M MOPS/2% acetonitrile 
(v/v), flow rate 1.0 ml/min. Peak E coincided with synthetic eyclo- 
(Pro-Gly). 
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Fig. 2. GC analysis of fraction E on a glass 2 mx4 mm I.D. col- 
umn, packed with 3% OV-17 on Chromosorb G 125-150 mesh 
washed 0.1 M NaOH. Gases flow rates were 40 ml/min (N2), 30 ml/ 
min (H2) and 300 ml/min (air). The temperature was 220°C (injec- 
tor), 205°C (oven), 250°C (detector). Peak 2 coincided with synthetic 
cyclo-(Pro-Gly). 
ologue of cyclo-(Pro-Gly), was used for recovery determination of the 
latter. The solution of 1.68 ~tg PDAH in 20 !11 of H20 was added to 
crushed brain ('sample') or 1.68 Ixg PDAH was dissolved in 100 lal of 
acetonitrile ('standard'). The sample was extracted as described above. 
The dry residue was redissolved in 100 # of acetonitrile and used for 
GC. These analyses were performed in triplicate and average peak 
area of the sample was compared with that of the standard. The 
recovery of PDAH in the above extraction procedure was 95%. 
2.8. Calibration graph 
Standard at concentrations of 0.02, 0.05, 0.1, 0.2, 0.5, 1.0, 2.0 and 
10.0 lxM of synthetic yclo-(Pro-Gly) in acetonitrile was prepared. A 3 
~tl volume of these solutions was injected onto the GC column. The 
calibration graph was calculated based upon peak areas. 
2.9. Antiamnesic activity 
Synthetic yclo-(Pro-Gly) was evaluated for its ability to prevent 
the memory decline provoked by maximal electroshock (MES) in the 
passive avoidance step-through paradigm in rats [15]. 
The experiments were carried out on adult male outbred rats (Krju- 
kovo, Moscow region) weighing 180-240 g. The step-through passive 
avoidance test, performed in a Lafayette Instrument Co. (USA) ap- 
paratus, was used for estimating memory retention according to Ader 
et al. [16]. The device consists of a lighted platform (25 x 7 cm) and a 
dark compartment (40 x 40 x 40 cm). A rat was placed on the lit start 
platform facing away from the dark compartment, which had an 
electrified grid floor. When the animal entered the dark compartment 
through a square guillotine door (6.5x6.5 cm) it received 8 unavoid- 
able painful footshocks (0.45 mA). Then the rat was removed from 
the chamber. In the retention test performed 24 h after training the 
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Fig. 3. Representative total ion GC-MS traces of synthetic yclo-(Pro-Gly) (A) and fraction E (B). Positive electron impact spectra of synthetic 
(C) and endogenous (D) cyclo-(Pro-Gly) obtained by GC-MS. 
animal was placed on the lit platform again. The latency to enter the 
dark compartment was registered. MES (70 V, 300 ms) was used 
immediately after training. Synthetic yclo-(Pro-Gly) dissolved in sa- 
line was administered intraperitoneally in a dose range of 0.05-1.0 
mg/kg, 15 min before the acquisition. Control animals were treated 
with saline. Antiamnesic activity (AA) was calculated according to the 
formula [17]: 
%AA - L(MES + compound)-L(MES) x100% 
L(control)-L(MES) 
where L(MES) is the average latent ime to enter the dark compart- 
ment for animals exposed to MES 24 h before; L(MES+compound) is 
the average latent time to enter the dark compartment for animals 
that had received the compounds and been exposed to MES; L(con- 
trol) is the average time to enter the dark compartment for saline- 
treated animals with sham MES. 
Statistical analysis was carried out using the Mann-Whitney U-test. 
3. Results and discussion 
HPLC separation of the acetonitrile xtract of native rat 
brain demonstrated a symmetric peak (peak E, Fig. 1), ab- 
sorbing at 220 nm, which retention time coincided with that of 
synthetic yclo-(Pro-Gly). The symmetry of this peak was not 
infringed at cochromatography of the isolated sample (frac- 
tion E) with synthetic cyclo-(Pro-Gly) on the Ultrasphere 
ODS and Eiconosil C18 columns, when various elution rates 
and mobile phase compositions were used. These findings al- 
low us to suggest hat fraction E contains endogenous cyclo- 
(Pro-Gly). In the course of GC the above mentioned HPLC 
fraction E was separated into two peaks, one of which (peak 
2, Fig. 2) according to its retention time coincided with syn- 
thetic cyclo-(Pro-Gly). GC cochromatography of HPLC frac- 
tion E and of synthetic cyclopeptide sample performed at 
various carrier gas rates and column temperatures showed 
that peak 2 and synthetic yclo-(Pro-Gly) invariable coeluted 
as one peak. So, GC data do not conflict with the assumption 
that cyclo-(Pro-Gly) is present in rat brain. 
To identify endogenous cyclo-(Pro-Gly) fraction E from the 
five rat brain extracts was isolated, collected and concen- 
trated. It was analyzed using mass spectrometric methods. 
Fraction E was examined by FAB mass spectrometry. The 
Table 1 
Antiamnesic activity of synthetic yelo-(Pro-Gly) 
Dose (mg/kg, i.p.) Animals (n) Latency (s) (mean + SEM) Antiamnesic activity (%) 
Control Amnesia Amnesia+ substance 
0.05 18 126.7+ 18.6 33.7+ 13.0 49.2+ 15.0 16.7 
0.1 16 83.1 + 34.3 18.2 + 7.7 67.5 +_ 25.8 75.9* 
1.0 10 161.1 + 18.9 77.5 + 26.0 131.7 + 21.3 64.8* 
*P< 0.05 in comparison with MES treated animals (U-test). 
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presence of a quasimolecular ion with m/z 155 corresponding 
to the mass of protonized cyclo-(Pro-Gly) was revealed. 
Then fraction E was analyzed by direct probe electron im- 
pact mass spectrometry. By temperature fractionation of frac- 
tion E in direct probe conditions with registration of total ion 
current a mixture of substances with evaporation tempera- 
tures from 130°C to 350°C was found. Selected ion monitor- 
ing showed the presence in this mixture of a substance that 
gave all characteristic molecule fragments of cyclo-(Pro-Gly), 
which are m/z 154, 126, 111, 98, 83 according to [18]. 
In GC-MS conditions total ion current monitoring of frac- 
tion E and synthetic yclo-(Pro-Gly) demonstrated peaks with 
identical retention time values (Fig. 3A,B). The mass spectra 
of these peaks were superposed in details (Fig. 3C,D). Thus 
MS data strictly prove that cyclo-prolylglycine is present in 
rat brain. 
The extraction efficiency (95%) of PDAH, of the cyclo-(Pro- 
Gly) homologue, was used for the determination of the con- 
centration of cyclo-(Pro-Gly) in rat brain. PDAH in GC con- 
ditions does not interfere with cyclo-(Pro-Gly) or unknown 
peaks. The cyclo-(Pro-Gly) concentration i  rat brain was 
determined by GC, using synthetic yclo-(Pro-Gly) for prepa- 
ration of the calibration curve. The calculated mean concen- 
tration of cyclo-(Pro-Gly) in rat brain was 2.8 +0.3 nmol/g 
wet brain. 
To evaluate the effect of cyclo-(Pro-Gly) on memory, the 
passive avoidance test was used. MES applied immediately 
after the acquisition procedure significantly diminished the 
latency of entering the dark compartment. Cyclo-prolylglycine 
administered before the training was shown to be able to 
reduce this amnesic effect of MES. Doses of 0.1 and 1.0 mg/ 
kg were found to be effective (Table 1). In our previous ex- 
periments cyclo-(-Pro-Gly) improved memory also under con- 
ditions of undertraining [13]. It is important o stress that 
cyclo-(Pro-Gly) exerted neither stimulating nor depressant ac- 
tion on general psychomotor activity. The cyclopeptide cyclo- 
prolylglycine seems to be a memory facilitating substance and 
its presence in rat brains suggests the existence of a new mech- 
anism of memory regulation. Identification of cyclo-(Pro-Gly) 
in the brain is of special importance, taking into consideration 
the recent report of Prasad [19], that only one cyclic dipeptide, 
cyclo-(His-Pro), has been conclusively shown to be endo- 
genous in mammals. 
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